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Abstract
Background: The association between pulmonary tuberculosis (PTB) and diabetes mellitus (DM) has been
previously attracted much attention. Diabetes alters immunity to tuberculosis, leading to more frequent treatment
failure in TB patients with DM. Moreover, TB and DM often coincide with micronutrients deficiencies, such as retinol
and vitamin D, which are especially important to immunity of the body and may influence pancreas β-cell function.
However, the effects of retinol and vitamin D supplementation in active TB patients with diabetes on treatment
outcomes, immune and nutrition state are still uncertain. We are conducting a randomized controlled trial of
vitamin A and/or D in active PTB patients with DM in a network of 4 TB treatment clinics to determine whether the
supplementation could improve the outcome in the patients.
Methods/design: This is a 2×2 factorial trial. We plan to enroll 400 active PTB patients with DM, and randomize
them to VA (2000 IU daily retinol); VD (400 IU daily cholecalciferol); VAD (2000 IU daily retinol plus 400 IU
cholecalciferol) or control (placebo) group. Our primary outcome measure is the efficacy of anti-tuberculosis
treatment and ameliorating of glucose metabolism, and the secondary outcome measure being immune and
nutrition status of the subjects. Of the first 37 subjects enrolled: 8 have been randomized to VA, 10 to VD, 9 to VAD
and 10 to control. To date, the sample is 97.3% Han Chinese and 91.9% female. The average fasting plasma glucose
level is 12.19 mmol/L.
Discussion: This paper describes the design and rationale of a randomized clinical trial comparing VA and/or VD
supplementation to active pulmonary TB patients with DM. Our trial will allow rigorous evaluation of the efficacy of
the supplementation to active TB and DM therapy for improving clinical outcomes and immunological condition.
This detailed description of trial methodology can serve as a template for the development of future treatment
scheme for active TB patient with DM.
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Background
The merging epidemics of pulmonary tuberculosis (PTB)
and diabetes mellitus (DM) and their synergistic role in
causing human disease has been attracted much attention
[1]. In China, where there are experiencing incredible in-
crease in DM prevalence, an age standardized prevalence
of diabetes of 9.7% (10.6% in men and 8.8% in women)
and prevalence of pre-diabetes as 15.5% (16.1% in men
and 14.9% in women) [2], also a high burden of PTB
exists. The combination of tuberculosis and diabetes
mellitus and double burden of TB and DM represent a big
health threat, which make the treatment failure more fre-
quent and result in more community acquired TB infec-
tion. Diabetes alters immunity to tuberculosis, which will
lead to higher mycobacterial burden and longer time to
culture conversion with treatment, and a higher rate of re-
lapse might result. In studies assessing time to sputum-
culture conversion, diabetic patients seem to take longer
time to achieve culture negativity. Guler et al. reported
that patients with diabetes who received tuberculosis
treatment had longer sputum-culture conversion times
than non-diabetic patients (67 vs 55 days; p=0.02) [3].
Similarly, Restrepo et al. [4] used survival analysis to
measure time to culture conversion, and found median
time to culture negativity was significantly longer in dia-
betic patients than that in controls. Radiographic findings
in tuberculous patients with diabetes differ from pure TB
patients. It was widely believed that pulmonary tubercu-
losis patients with diabetes presented with an atypical
radiographic pattern and distribution and lower lung field
tuberculosis was seen more frequently in TB patient with
DM. Overlapping toxicities and various drugs used may
worse diabetic control and alter the pharmacokinetics of
antituberculosis drugs, which makes the clinical treatment
of TB patients with DM more difficult.
TB and diabetes often coincide with malnutrition. TB
patients frequently suffer from deficiencies of nutrients,
such as vitamins A and D, which are fundamental to the in-
tegrity of the immune response, especially the host immune
response toward Mycobacterium. Studies have shown that
vitamin A has an immune protection role against human
tuberculosis. In addition, vitamin A supplementation results
in a modulation of the immune response in patients with
tuberculosis [5,6]. The classic role of vitamin D in the regu-
lation of calcium and phosphate metabolism, and its effects
on bone health, have been well established. More recently,
a critical role of vitamin D in immunity, respiratory health
and insulin resistance has been proposed [7,8]. Low serum
vitamin D has been discovered to be associated with higher
risk of active tuberculosis. Researches revealed that vitamin
D plays a key role in the production of a molecule called
cathelicidin, which kills the mycobacterium tuberculosis or-
ganism [9,10]. Furthermore, a double-blind randomized
controlled trial conducted in 192 healthy adult TB contacts
in London discovered that a single oral dose of 2.5 mg vita-
min D significantly enhanced the ability of participants'
immunity to mycobacteria [11]. However, a trial in Guinea-
Bissau found no effect of vitamin D (100,000 IU of
cholecalciferol at inclusion and again 5 and 8 months after
the start of treatment) on clinical outcome and mortality in
patients with TB [12].
Furthermore, vitamins play an important role in glu-
cose metabolism. It has been reported that vitamin D
can regulate the β cell function in pancreatic islet, the
insulin activity and the systematic inflammation level.
Plasma 25(OH) D levels are positively association with
both β-cell function and insulin sensitivity [13]. A trial
carried out in USA found that in adults at risk of type 2 dia-
betes, short-term supplementation with cholecalciferol
improved β cell function and had a marginal effect on at-
tenuating the rise in Hb A(1c) [14]. Also, Vitamin A and its
metabolites, retinoids, have emerged as key participants in
the mechanisms of regulation of cellular metabolisms and
energetics, which may also play a key role in the process of
glucose metabolism.
We designed this VA/D supplementation trial to test the
efficacy of micronutrient intervention on active TB
patients with DM. We are implementing this randomized
controlled trial in a network of TB therapy clinics that
offer TB treatment by primary care providers, including
standard DM treatment. The primary objective of our trial
is to determine whether VA, VD or VAD supplementation
is efficacious on anti-tuberculosis treatment and insulin
resistance. The secondary objective is to investigate the
underlying mechanism including immunological function,
nutritional status, etc. We here provide a detailed meth-
odological description of this trial, which can serve as a
template for other investigators designing the comprehen-
sive treatment of TB and DM. In addition, we discuss the
efficacy of VA and/or VD supplementation on TB and
DM to guide future clinical treatment. Finally, we report
baseline characteristics of our recruited study population.
Methods/design
Study setting
The VA/D supplementation trial is being conducted in a
network of 4 TB clinics in Qingdao and Linyi city in Shan-
dong province in China. Together, these clinics provide
care for approximately 5,000 active pulmonary tubercu-
losis patients per year and nearly 10% have DM. These
four clinics are the sites for study recruitment, delivery of
the VA and/or VD intervention, and all research visits.
VA and/or VD supplementation is delivered by the
physicians, together with the nurses, social workers to
take care of the patients. The medical team provides
comprehensive medical care, including TB and DM
pharmacotherapy.
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VA/D supplementation scheme
This is a 2-by-2 factorial-design intervention trial. Active
pulmonary tuberculosis patients with diabetes mellitus are
offered onsite TB and DM evaluation and treatment by pri-
mary care providers, and are free to choose whether to re-
ceive VA/D supplementation. Primary care providers
receive special training by the project team, including the
related knowledge of TB and DM, especially the association
between TB and DM; the related nutritional deficiencies
and the role of micronutrients in cell-mediated immunity.
Once sign the informed consents, the patients will
be randomly assigned to VA (2000 IU daily retinol on
top of normal pharmacotherapy) or VD (400 IU daily
cholecalciferol on top of normal pharmacotherapy) or
VAD (2000 IU daily retinol plus 400 IU daily cholecalciferol
on top of normal pharmacotherapy) or control (placebo on
top of normal pharmacotherapy) group.
Trial inclusion and exclusion criteria
Potential trial subjects are eligible for inclusion if they are
affected with active pulmonary tuberculosis and have
fasting plasma glucose (FPG) of ≥126 mg/dL or 2-hour glu-
cose level of 200 mg/dL or above by OGTT; have no his-
tory of previous anti-tuberculosis treatment and oral
hypoglycemic drugs or insulin used; plan to initiate onsite
anti-tuberculosis and DM treatment at the TB clinic within
the next six months; attend their TB clinic after
hospitalization once or twice per month to receive supple-
mentation pill and physical examination; plan to stay in
local place for 2 years. Participants are excluded if they are
unable or unwilling to provide informed consent; are drug
resistant at baseline or during the follow up; pregnancy; lac-
tation; use of corticosteroids or supplements containing
vitamin A or vitamin D during the previous month; chronic
renal failure as indicated by elevated serum uric acid or cre-
atinine concentrations; and clinical signs of neoplasm and
congestive heart failure.
Approvals and data safety and monitoring
The trial was approved by Ethics Committee of the
affiliated hospital of Medical College of Qingdao Univer-
sity. All participants provide written informed consent.
Besides of VA and/or VD supplementation, we are giving
nutritional and behavioral suggestion and instruction
that is highly integrated with normal clinical care to all
the subjects. Also, we established a data safety and
monitoring plan, which requires interim analyses after
every twenty patients are enrolled.
Recruitment
Medical providers in the four TB clinics are asked to in-
vite all patients initiating on-site anti-TB and DM treat-
ment to consider enrolling in the trial. Subjects also are
referred by other subjects or through the project group.
The initial steps in subject recruitment include a brief
screening survey, informed consent, and in depth verifi-
cation of eligibility using medical records and discussion
with providers.
Randomization
Random-number tables are used to allocate subjects to
the VA intervention arm, VD arm, VAD arm or the
placebo control arm.
Baseline assessment
The baseline assessment consists of an interview and phys-
ical measurement. Baseline fast blood glucose, results of
urine toxicology tests, liver function test and other related
clinical indexes are obtained by chart review. The baseline
interview is conducted prior to vitamin supplementation
initiation, and at this visit all subjects are invited to attend
VA/D supplementation trial. Following completion of the
baseline assessment, participants receive their assignment
to one of the four arms.
Visit schedule and measures
Frequency and length of research visits during the 24 to
32 weeks (according to the anti-tuberculosis drug treat-
ment period) intervention period are the same for
subjects in each arm. We standardized the visit schedule
to control for any improvement in adherence, possible
side effects which might result from VA/VD supplemen-
tation alone. We use several measures to assess VA/VD
adherence: self-report, pill count, and nursing records of
directly observed doses and returned pill boxes.
Treatment-related side effects
A treatment side effect scale (which measures the degree
of VA and/or VD treatment-related side effects) is
administered at each monthly visit, and the results are
given to medical providers. Side effects include fatigue,
irritability, anorexia, headache, fever, insomnia, nausea,
vomiting, and other common side effects.
Sample size and power calculations
We calculated the sample size on the basis of literature
research in the related domain and analyzing the object-
ive and indexes in this trial by using formula:






α ¼ 0:05 Zα=2 ¼ 1:645
 
;
1 β ¼ 0:90 Zβ ¼ 1:282
 
We calculated the needed sample size for the main in-
dexes and selected the largest one. We will need 84
subjects in each arm to have 90% power to show signifi-
cant difference among trial arms. Considering
participants’ compliance, none response and withdraw, a
sample size of 100 per arm is needed.
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Planned statistical analyses
We hypothesize that effect of anti-TB and DM treatment
in VA and/or VD arms will be better than the effect in
the control arm. Descriptive statistics will be calculated
and checked for balance in each arm in demographic,
physical and other related measurements at baseline.
Comparisons among the groups of pulmonary patho-
logical damage, CD4
+ T cell, HOMA-IR, etc., will be
performed by Chi-square (categorical variables), F test
(continuous variables, normal distribution) or Kruskal–
Wallis H test (ranked data). Linear mixed-effects models
will be used to analyze the main influencing factors.
We will also calculate anti-tuberculosis and diabetes
treatment results, nutritional and immunologic indexes at
three time points: before the supplementation (at the in-
clusion), 2 months after the supplementation, and at the
end of the trial (6 to 8 months after the supplementation).
Study sample characteristics
Screening and baseline interviews began in Oct, 2012, and
are ongoing. We here present the baseline characteristics of
the first 37 subjects who have been enrolled and initiated
on-site anti-TB and DM treatment: Of these, 8 were
randomized to the VA arm, 10 to VD arm, 9 to VAD arm
and 10 to the control arm (Figure 1).
The sample is 91.9% male, 97.3% ethnic Han, with a
mean age of 52 (Table 1). 83.8% subjects have education
level of senior high school or lower, 75.7% married, 48.6%
employed. 75.7% subjects’ BMI were normal(18.5~24.99)
with one patient being severe wasting, 5 patients being
mild wasting and 3 patients being overweight.
At baseline, 94.6% of the sample had cough, 89.2% had
expectoration, 29.7% had hemoptysis, 48.6% had fever,
75.7% had weak, 51.4% had night sweat, 21.6% had
thoracalgia, 54.1% had chest stufly. As to pulmonary path-
ology inspected by CT, 73% of the sample had pulmonary
cavity, 2.7% had infiltration. Admission biochemical exam-
ine showed that the mean fast plasma glucose concentration
was 12.19 mmol/L, mean LDL-C level was 2.42 mmol/L,
median TC concentration was 4.29 mmol/L, median TG
concentration was 1.66 mmol/L, mean HDL-C level was
1.21 mmol/L.
Our intervention is feasible and can be implemented
in a busy clinical setting. Staff at the four clinics worked
collaboratively with the study team, and to date 37
participants have been enrolled from the four clinics.
Health care providers communicate well with the med-
ical director and research assistants, and nurses at each
clinic record daily events on study calendars. To date, a





- not interested in VA/D supplementation trial (5)
- Medical Contraindications
- extrapulmonary tuberculosis(1)
- resistance to regular anti-TB drugs(2)
-cardiovascular and cerebrovascular diseases
(2)
-immunological disease (1)
-planning to go to other area (3)










Figure 1 Flow chart of study recruitment and enrollment.
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The VA/D program is acceptable to our patients. To
date, 88% of all patients who were eligible for receiving
VA/D supplementation and met study inclusion and ex-
clusion criteria have chosen to participate. No
participants have refused their randomization.
The core components of our VA/D program do not re-
quire additional staff over existing clinic operating models.
We will provide subsidies for medical providers, nurses,
or support group facilitators on support of the Natural
Science Foundation of China (NSFC) and Danone Nutri-
tion and Education fund. We pay the VA and VD
supplements used for the study.
Discussion
To our knowledge, this study represents the first
randomized controlled trial of a directly observed VA/D
supplementation program in active pulmonary tubercu-
losis patients with diabetes that focused on the contribu-
tion of anti-TB and DM treatment effect and the possible
mechanisms.
Tuberculosis and diabetes interact with each other,
which might make clinical treatment become more diffi-
cult than the single disease of pulmonary tuberculosis or
diabetes. As diabetes alters immunity to tuberculosis,
longer times to culture conversion with treatment, and a
higher rate of relapse might result. Treatment failure and
death are more frequent in diabetic patients than patients
with PTB alone. Alisjahbana reported that in patients with
high adherence to treatment, 6-month sputum cultures
were positive in 22.2% of patients with diabetes mellitus
and in 6.9% of controls and these differences remained
after adjustment for age, sex, body mass index, and other
factors [15]. In a case–control study [16] treatment failure
or death was seen in 41% of the patients with tuberculosis
and diabetes mellitus, but in only 13% of those with tuber-
culosis alone. A recent study by Wang and colleagues [17]
discovered that 1-year all-cause mortality was 17.6% in
diabetic PTB patients versus 7.7% in non-diabetic
controls, and death specifically attributable to pulmonary
Table 1 Baseline characteristics of study sample (n =37)
Sociodemograpic








Senior high school or lower 31 (83.8)
Junior College and college 6 (16.2)





Retired/Unable to work/unemployed/other 16 (43.2)

















PTB-related CT pathology, n (%)
Pulmonary cavity + 27(73)




FPG, mmol/L(mean,sd) 12.19, 3.30
LDL-C, mmol/L (mean,sd) 2.42, 0.63
TC, mmol/L (M, interquartile range) 4.29, 0.85
TG, mmol/L (M, interquartile range) 1.66, 0.79
HDL-C, mmol/L (mean,sd) 1.21, 0.29










b<16: severe wasting; 16~16.9: moderate wasting; 17~18.4: mild wasting;
18.5~24.99: normal; 25~29.99: overweight; ≥ 30: obesity.
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tuberculosis was significantly more common in diabetic
patients (12.2% vs 4.2%).
The most important effector cells for containment of tu-
berculosis are phagocytes, monocytes and lymphocytes.
Diabetes is known to affect chemotaxis, phagocytosis, acti-
vation, and antigen presentation by phagocytes in response
to M tuberculosis. Vitamin A is an essential micronutrient
for a variety of physiological processes, such as tissue differ-
entiation, immunity, and vision. Also, the impacts of VA
and retinoids on energy metabolism in animals and
humans have been demonstrated in some basic and clinical
investigations [18]. Also, it has been proposed recently that
vitamin D play a critical role in immunity, respiratory
health and insulin resistance. Vitamin A, its metabolites
and vitamin D directly inhibit mycobacterial growth in
culture [19].
A recent randomized trial of vitamin A and Zinc sup-
plementation focused on the effect on treatment
outcomes in TB patients and found that supplementa-
tion with vitamin A and zinc did not affect treatment
outcomes in participants with pulmonary tuberculosis at
8 wk [20]. An important difference between this trial
and our study is that single dose of 200,000 IU retinyl
palmitate was used in the reported trial, while daily sup-
plementation of 2000 IU retinol is being supplemented
in our study. Also, vitamin A and Zinc supplementation
on serum fasting blood sugar, insulin, apoprotein B and
A-1 in patients with type I diabetes has been carried out
[21], and found that combined zinc and vitamin A sup-
plementation can improve serum apoprotein A-I, apo-
protein B and the apoprotein B/apoprotein A-I ratio in
patients with type I diabetes.
Some randomized controlled studies have focused on
effect of vitamin D on glucose indices and vascular
markers in type 2 diabetes[22,23], which found that
Vitamin D supplementation attenuated the increase in
glycemia, and increased insulin secretion, improved sys-
tolic blood pressure and B-type natriuretic peptide
levels. Mitri et al. [14] implemented a 2-by-2 factorial-
designed, double-masked, placebo-controlled trial and
discovered that cholecalciferol (2000 IU once daily) sup-
plementation for 16 wk can improved β cell function
and had a marginal effect on attenuating the rise in Hb
A(1c) in adults at risk of type 2 diabetes.
Vitamin D has been shown to be involved in the host
immune response toward Mycobacterium tuberculosis.
Recently several VD supplementation trials to active TB
patients are available. Administration of four doses of
2.5 mg vitamin D3 significantly hasten sputum culture
conversion in patients with the tt genotype of the TaqI
vitamin D receptor polymorphism [24]. However, C
Wejse et al. [12] reported that supplementation of three
doses of 2.5 mg vitamin D3 at baseline, 5 months, and 8 -
months did not influence clinical severity score or time
to sputum smear conversion in 365 patients in Guinea
Bissau. It is possible that the dose used was insufficient.
In our trial, we are supplementing VD by daily dose of
2000 IU cholecalciferol, and we are measuring the effect
of the supplementation on clinical treatment in active
TB patients with diabetes. In addition, prior studies have
found that supplementation of VA or VD is associated
with improved β cell function or hasten sputum culture
conversion, our trial will allow us to determine whether
this association will remain true for VA and/or VD use
in patients with both TB and DM who have more severe
clinical symptom and poorer prognosis, and the under-
lying mechanism is being investigated.
Despite its strengths, trial limitations should be noted.
In our trial, only some doses of VA and VD are observed.
However, we designed these doses on the basis of acquir-
ing important information including the VA nutrition sta-
tus in China by national survey [25], the recommended
VA and VD intake formulated by the Chinese nutrition
society. Also, abundant literature researches concerning
the VA, VD level in the supplementation trials have been
implemented. In addition, different distribution of some
aspects of the subject in the four arms such as severity of
the disease, fundamental nutrition status, socioeconomics
status etc. may interfere or reduce our measured effect
size. To minimize the differential effect between the four
arms, we balanced the four arms regarding age, sex and
randomized the subjects to different groups. Furthermore,
multivariate logistic regression will be used to identify the
measured size to adjust the possible impact factors.
We expect that results of our VA and/or VD supple-
mentation trial will advance our knowledge of the efficacy
of directly observed therapy for active PTB and DM. If
our results provide evidence that VA and/or VD supple-
mentation is effective in PTB and DM, further research
protocols can be developed to observe the efficacy of other
kind of micronutrients related to glucose metabolism and/
or anti-mycobacterium on the patient with both PTB and
DM. Data from this study will also allow us to examine
the optimal biomarkers associated with PTB and DM
treatment influenced by micronutrients. Newer regimens
for PTB and DM treatment will emerge which may im-
prove outcomes of clinical therapy and/or shorten the
treatment period.
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